Key takeaways
- The main digestive research concerns globe artichoke leaf extracts, not artichoke hearts, Jerusalem artichoke or every product labelled “artichoke”
- One notable placebo-controlled dyspepsia trial was positive, but it was sponsored by the manufacturer and included a company author
- Frequently quoted IBS results come from uncontrolled or post-hoc analyses. They do not establish a treatment effect over placebo
- Evidence that an extract changes bile output or a liver imaging marker does not establish better digestion, SIBO eradication or a “liver detox”
- Bile-duct obstruction, gallstones, liver disease, Asteraceae allergy and relevant medication use are important reasons to avoid self-treatment
Artichoke leaf extract has preliminary evidence for dyspepsia from a positive manufacturer-sponsored trial; Cochrane rated that single-trial evidence low certainty. The cited IBS studies lack placebo controls, and the small liver studies measure short-term surrogates. Results concern particular preparations and do not establish dependable relief from every retail product, treatment of SIBO or a “liver detox.” Traditional medicinal use and product-specific contraindications remain separate questions (Holtmann trial; Cochrane review; IBS subset; EMA monograph).
Contents
Evidence summary · Identity · Forms · Mechanism · Hype · Benefits · Verdicts · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources
Evidence summary
The grade applies to the particular claim after funding and formulation checks. Manufacturer-supported studies are described fairly but excluded from the independent benefit basis. Unknown financing or product procurement is not treated as proof of either independence or sponsorship.
| Claim | Evidence | Source | Funding/conflict | Strength |
|---|---|---|---|---|
| Relieves functional dyspepsia | Positive six-week randomized trial; one-study Cochrane assessment rated low certainty | Holtmann 2003; Cochrane 2023 | Lichtwer sponsorship and company author | Insufficient independent evidence |
| Treats IBS | Post-hoc analysis of an uncontrolled postal study | Bundy 2004 | Lichtwer-affiliated coauthor; full budget not resolved | Insufficient |
| Higher doses work better for indigestion | Two open-label dose groups improved without a difference in primary outcomes | Marakis 2002 | Full funding/procurement unresolved; linked study program had company involvement | Insufficient for dose-response or placebo-adjusted benefit |
| Stimulates bile secretion | Small acute human experiment using direct duodenal administration | Kirchhoff 1994 | Branded preparation; complete funding chain unresolved | Limited physiological evidence |
| Improves gastric motility as a single ingredient | Small study tested a botanical combination | Lazzini 2016 | Indena employees and funded editorial support | Insufficient for artichoke alone |
| Treats fatty liver disease | Short laboratory/imaging studies; Panahi has allocation and participant-reporting problems | Panahi 2018; Holländer 2026 | Panahi: Niak and university support. Holländer: no specific grant or financial relationships declared; registry institutional budget, procurement unresolved | Insufficient for a broad disease-treatment claim |
| Eradicates SIBO or repairs the gut lining | The studies discussed below do not demonstrate these clinical outcomes | Scope of studies below | Cell and combination findings cannot establish isolated-extract clinical efficacy | Insufficient |
What it is
The medicinal material in this review is the leaf of globe artichoke, Cynara cardunculus L., also described as Cynara scolymus. EMA distinguishes dried or powdered leaf from solvent-derived extracts. The identity of the plant part is important: an edible flower bud, purified fiber, leaf powder and an aqueous leaf extract are different interventions. EMA identity and preparations
The question is whether a defined swallowed preparation improves a meaningful digestive outcome compared with a suitable control. It is not whether the plant contains biologically active compounds. Many plants do; that fact alone cannot settle clinical effectiveness.
Jerusalem artichoke is a different ingredient source. A registry describing Jerusalem-artichoke inulin and bowel function should not be counted as a trial of globe-artichoke leaf extract. Nor should a leaf-extract capsule inherit the evidence for isolated inulin simply because the whole plant can contain carbohydrates. Separate Jerusalem-artichoke inulin study record
Forms and grades
| Preparation | Defining feature | Why it matters |
|---|---|---|
| Dried or powdered leaf | Whole medicinal leaf material | Milligrams cannot be equated to concentrated extract |
| Dry aqueous leaf extract | Water-soluble constituents concentrated from leaf | Extraction ratio and actual extract amount are relevant |
| Hydroalcoholic or soft extract | Different solvent and processing | Chemistry can differ from the pivotal trial preparation |
| Extract standardized to phenolics, cynarin or related markers | A specification measures selected compounds | “As cynarin” may describe an analytical expression, not pure cynarin content |
| Multi-ingredient digestive formula | Artichoke combined with other active substances | Any result initially belongs to the complete formula |
| Artichoke food, juice or purified inulin | Different plant material and composition | No automatic transfer of extract efficacy |
A drug–extract ratio describes the amount of starting plant used relative to extract obtained. It does not guarantee bioequivalence, potency in a patient or a linear conversion between brands. For example, the current German Hepar-SL 320 mg information identifies a water extract with a 4–6:1 ratio. That specification is more useful than a large “equivalent herb” number, but still does not prove that another brand matches the trial. Current product specification
The newer SteatoChoke paper describes standardization as total polyphenols expressed as cynarine. That should not be silently rewritten as a dose of chemically pure cynarin. Extraction method, plant part, analytical method and coingredients all belong in a credible comparison. Holländer formulation description
How it works
Proposed actions include altered bile secretion, smooth-muscle effects and activity of phenolic constituents. These are hypotheses about how an effect might occur. They are not interchangeable with proof of symptom relief.
In a 20-person crossover pilot, a branded extract was placed directly into the duodenum and bile secretion was measured over hours. Some time points favored active treatment. This is human physiology, but the administration route bypassed normal swallowing and the study did not establish sustained relief of IBS, constipation or dyspepsia from ordinary capsules. Kirchhoff 1994
Bile is involved in digestion, but more secretion is not automatically better for every person. An intervention proposed to influence bile flow is particularly unsuitable for casual experimentation when a duct is obstructed or gallstones are present. EMA's restrictions reflect this important boundary. EMA assessment
Hype versus evidence
Artichoke is marketed for fullness, bloating, fat digestion and liver support. A current manufacturer also promotes rapid activation of digestion and effects on the intestinal flora. Those are commercial claims to investigate, not independent evidence. Hepar-SL marketing
Three common leaps are not justified:
- A bile-secretion experiment does not show that the ordinary cause of bloating is inadequate bile
- A favorable dyspepsia score does not establish eradication of a bacterial overgrowth syndrome
- Lower liver fat on an imaging test does not show “detoxification,” prevention of cirrhosis or better long-term clinical outcomes
Dyspepsia can have several causes. Persistent symptoms should not be assigned to low bile, poor motility or a damaged gut lining solely because a supplement is advertised for those explanations. NIDDK explanation of indigestion
Benefits by claim
Functional dyspepsia Insufficient independent evidence
Holtmann’s study recruited 247 adults, with 244 included in analysis. A defined extract at 640 mg three times daily was compared with placebo for six weeks. The summed weekly symptom-improvement score favored extract, 8.3 versus 6.7; quality of life also improved more. These are scale measurements, not percentages cured. Lichtwer Pharma sponsored the trial, and a coauthor had a Lichtwer affiliation (Holtmann 2003).
Cochrane’s 2023 review found low-certainty evidence of a small improvement in global dyspepsia symptoms from the single artichoke trial: SMD −0.34 (95% CI −0.59 to −0.09). Unclear selective-reporting risk and imprecision limited confidence. The reviewers reported university support, no external support and no known conflicts; one Cochrane editor-author did not participate in editing this manuscript. Those review-level disclosures do not change the underlying trial’s Lichtwer sponsorship (Cochrane results, study characteristics and disclosures).
Marakis' open postal study recruited 516 people with self-reported dyspepsia; 454 completed it. Both 320 mg/day and 640 mg/day groups improved over two months, without a difference between groups on primary measures. There was no placebo group. Randomizing the dose does not solve the absence of a no-extract comparison. Marakis 2002
Together, these findings justify further investigation. They do not establish a predictable independent benefit from any retail artichoke extract or show that doubling a dose improves the principal digestive outcome.
Irritable bowel syndrome Insufficient
The 2004 result was a post-hoc subgroup of the earlier postal study: 208 participants were identified as having IBS alongside dyspepsia. The authors reported improvements in symptoms, bowel pattern and quality of life. The reported fall in “IBS incidence” was a before-and-after finding, not a placebo-adjusted cure rate or evidence of disease prevention. A coauthor was affiliated with Lichtwer Pharma UK (Bundy 2004).
Walker’s earlier report analyzed 279 people with IBS-like symptoms from 553 patients in German outpatient practice. The authors could not establish how many met a full IBS diagnosis because the original forms lacked all diagnostic criteria. Symptom scores improved over six weeks, but there was no control group, and a coauthor was affiliated with Lichtwer Pharma UK. This German cohort and the later postal-study subgroup are distinct uncontrolled reports, not independent placebo-controlled confirmations (Walker 2001; Bundy 2004).
Gastric emptying, constipation and SIBO Insufficient for the isolated extract
Lazzini’s crossover pilot studied 11 healthy volunteers given artichoke leaf extract plus ginger. The post-meal ultrasound measure was gastric area at one hour, not relief of a diagnosed digestive disorder or a measurement of the migrating motor complex. It did not isolate artichoke’s contribution. Indena employees were authors, and the company funded editorial assistance; the simultaneous no-conflicts declaration does not negate those relationships (Lazzini 2016).
Neither that physiological experiment nor an uncontrolled report of changed bowel habits establishes treatment of chronic constipation or eradication of SIBO. Faster emptying, a bowel movement, less bloating and microbiological eradication are different outcomes. Adequate trials would need the correct diagnosis, a suitable comparator, prespecified clinical outcomes and follow-up.
Liver-related digestive claims Insufficient for routine treatment
Panahi’s eight-week study compared 600 mg/day Cynarol artichoke extract with placebo in people with ultrasound-diagnosed fatty liver. Although described as randomized, its Methods say assignment alternated between groups; the analysis was per protocol, with substantial baseline biochemical imbalances. Participant totals conflict across the abstract, main text, tables and flow diagram. The paper reports favorable laboratory and ultrasound changes, but these reporting and design problems weaken interpretation, and no long-term liver outcome was established. Niak Pharmaceuticals and Baqiyatallah University supported the study despite its no-competing-interests declaration (Panahi original paper).
The SteatoChoke pilot studied 40 bariatric-surgery candidates, with 20 per group, for six weeks. The liver-fat imaging marker CAP was lower with extract at three and six weeks; ultrasound lobe-diameter differences depended on the lobe and time point. Both groups introduced a restrictive preoperative diet for the final three weeks. AST was higher with extract than placebo at six weeks, whereas ALT’s between-group comparisons were nonsignificant; a laboratory change does not establish clinical liver injury. The trial was single-blind and registered retrospectively. The final paper declares no specific grant and no commercial or financial relationships; the registry reports an institutional budget. Product purchase or donation terms remain unknown. This small exploratory surrogate study does not establish treatment of liver disease or ordinary digestive symptoms (Holländer original methods, results and declarations; primary abstract; trial registry).
Research conducted under medical supervision does not cancel contraindications on medicines intended for self-care. The EMA digestive-use monograph lists liver and biliary disorders requiring professional assessment. EMA monograph
What works and what does not
| Claim | Verdict | Notes |
|---|---|---|
| Defined leaf extract may relieve functional dyspepsia | Preliminary signal | Pivotal evidence commercially sponsored |
| Established independent IBS treatment | Not established | Uncontrolled and post-hoc studies cannot quantify treatment effect |
| Corrects a proven general bile deficiency | Unsupported generalization | Bile physiology is not a diagnosis |
| Treats SIBO or restores the migrating motor complex | Not established here | No directly applicable eligible clinical demonstration |
| Dissolves gallstones or safely clears an obstruction | Unsupported and unsafe as self-treatment | Biliary restrictions are central safety information |
| Prevents liver complications | Not established | Short surrogate studies cannot answer this |
| Any standardized artichoke product is interchangeable | Unsupported | Plant part, solvent, extract ratio and chemical specification vary |
Risks and side effects
| Aspect | Finding | Source |
|---|---|---|
| Digestive intolerance | Diarrhea with cramps, upper abdominal discomfort, nausea and heartburn are reported | Current Hepar-SL information |
| Frequency | Current product information and EMA describe frequencies as unknown | Product information; EMA public summary |
| Allergy | Artichoke or Asteraceae hypersensitivity is a contraindication | EMA monograph |
| Biliary and liver disorders | Obstruction, cholangitis, gallstones and other listed conditions preclude casual self-treatment | EMA assessment |
| Pregnancy, lactation and children | Adequate safety data are lacking; product restrictions apply | Current label |
| Excipients | The examined 320 mg medicine contains lactose | Product specification |
The small studies do not establish rare-event incidence or indefinite safety. A statement that no events occurred in a short trial is not evidence that harm is impossible.
Safety: Severe or persistent abdominal pain, fever or jaundice can signal a condition requiring urgent assessment, including a gallstone complication. Breathing difficulty or swelling of the tongue or throat requires emergency care. Vomiting blood or black, tarry stools requires urgent medical assessment. Persistent vomiting or worsening swallowing difficulty also needs prompt assessment rather than another digestive supplement (NHS gallstone warnings; NHS anaphylaxis guidance; NIDDK alarm symptoms).
Interactions and evidence gaps
| Substance or condition | Mechanism or concern | Severity/status | Source |
|---|---|---|---|
| Warfarin or phenprocoumon | The examined German medicine warns that anticoagulant effectiveness may be reduced | Product-label warning; magnitude and mechanism are not established by a trial here | Hepar-SL professional information |
| Gallstones, bile-duct obstruction or cholangitis | Proposed bile stimulation does not treat mechanical obstruction | Important contraindication/suitability issue | EMA monograph |
| Other prescription medicines | Dedicated clinical interaction evidence is incomplete | Absence of a report is not demonstrated compatibility | EMA monograph |
| Rosuvastatin | An interaction experiment considered by EMA involved rats | Preclinical only; does not establish a human dose adjustment | EMA 2025 addendum |
| Multi-herb digestive products | Other active ingredients can introduce separate adverse effects or interactions | Product-specific review required | Combination-study example |
There is a meaningful source difference: EMA's adopted monograph says interactions were not reported, whereas the current Hepar-SL professional document includes the coumarin warning. Neither should be hidden. The prudent conclusion is to check the actual product with the prescriber or pharmacist, rather than declare every extract safe or assume an identical interaction for every preparation. Anticoagulant doses should not be adjusted on the basis of this article.
This table is selective. It does not certify compatibility with diabetes medicines, immunosuppressants, cancer treatment or every other medicine. Speculation from cell or animal experiments should not be presented as a confirmed human interaction.
Who should avoid self-treatment
People with biliary obstruction, cholangitis, gallstones, liver disease or known artichoke/Asteraceae allergy should follow the relevant contraindications and seek medical advice. Those using coumarin anticoagulants need a medication review. The medicine reviewed here is not intended for children under 12 and advises against use in pregnancy or breastfeeding because of insufficient study. These restrictions concern medicinal preparations; they should not be casually converted into a universal ban on ordinary foods. EMA monograph, product information
Undiagnosed, recurrent or progressive symptoms deserve assessment rather than a presumed supplement deficiency. Research-dose tables do not replace that decision.
Dosage and how it was taken in research
These quantities describe experiments, not a recommended regimen or interchangeable brand equivalents.
| Use case | Studied exposure | Duration | Notes |
|---|---|---|---|
| Functional dyspepsia | Two 320 mg extract units three times daily, 1,920 mg/day | 6 weeks | Manufacturer-sponsored trial; Holtmann |
| Self-reported mild dyspepsia | 320 or 640 mg/day | 2 months | Open postal study; no placebo; Marakis |
| Bile-secretion physiology | 1.92 g directly into the duodenum | Single experimental administration | Not an oral home-use protocol; Kirchhoff |
| Fatty-liver laboratory/imaging study | 600 mg/day Cynarol | 8 weeks | Niak and university support; alternating assignment and inconsistent participant reporting (Panahi) |
| Prebariatric liver imaging | 2,600 mg/day specified extract | 6 weeks | Final three weeks also included a restrictive diet; small surrogate study (Holländer) |
These doses answer different formulation-specific research questions; they do not define a safe “effective range.” Historical trial directions may differ from a current medicine’s label. For example, the March 2024 Hepar-SL 320 mg document specifies two capsules twice daily with main meals, whereas Holtmann’s trial used two 320 mg units three times daily. Neither establishes interchangeability with another product (current Hepar-SL directions; historical trial).
Animal and in vitro evidence excluded from benefit conclusions
A Spanish publicly supported study tested artichoke processing-waste extracts in cultured Caco-2 cells and measured responses to oxidative stress. It did not measure clinical gut-barrier repair in people taking leaf capsules. The authors declared no conflicts and listed Spanish national/regional, European and research-network support; those disclosures do not turn cell outcomes into patient benefits (original cell study and funding disclosures).
EMA's 2025 review also discusses rodent liver and drug-interaction experiments. These cannot establish a safe human statin combination, clinical liver protection or a digestive treatment effect. This article's benefit grades do not rely on animal or cell outcomes. EMA addendum
Independent funding tracing
Research funding at a glance
32 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Who supported the key studies
Lichtwer sponsored the pivotal dyspepsia trial, and a coauthor had a Lichtwer affiliation. The IBS reports also include a Lichtwer UK-affiliated coauthor, although Walker’s patients were in Germany. Lazzini’s combination study names Indena employees and company-funded editorial assistance. Panahi discloses pharmaceutical and university support. SteatoChoke declares no specific grant or financial relationships, with institutional funding in its registry; its procurement terms remain unknown. These are separate financial relationships, not interchangeable “academic” or “independent” labels (Holtmann; Cochrane sponsor extraction; Walker; Bundy; Lazzini; Panahi; SteatoChoke declarations; registry).
The exclusion rule is symmetrical. Industry-supported positive results do not establish independent benefit; an industry-supported null result would not establish independent lack of benefit either. Buying an off-the-shelf ingredient at arm's length is not sponsorship. Unknown payment terms remain unknown.
Ownership, countries and documented backers
Lichtwer Pharma AG was a German company in the pivotal trial; the UK papers identify a UK affiliate. The investor 3i's 2004 annual report records an investment in the herbal-medicine business. A transaction adviser reports that 3i, Clarat Partners and management sold Lichtwer Healthcare's brand portfolio and pharmaceutical rights to MCM Klosterfrau in June 2006. This establishes a historical transaction, not today's shareholder percentages or who financed a 2003 trial. 3i 2004 report, adviser's transaction record
Klosterfrau's current site places Hepar-SL in its portfolio and describes central headquarters functions in Cologne, Germany. Its brand page dates the product's group membership to 2005, while the adviser's wider rights-transaction entry is dated 2006. Those may refer to different steps, but the exact reconciliation was not established. Cassella-med is named in the current medicine information. No current ownership percentage is inferred from these records. Current brand, group structure, medicine document
The Wilhelm Doerenkamp Foundation's own grant site documents its historical connection to preserving the Klosterfrau business and supporting research. That does not by itself establish the complete current legal ownership chain or an artichoke-trial grant. Its charitable purpose does not remove the commercial interests of a medicine business. Foundation's account
Indena’s own history identifies IdB Holding as its parent and describes the Della Beffa family’s involvement. An Indena governance model also describes parent-company control and management/coordination. These are primary corporate self-disclosures, not a complete current beneficial-ownership audit. Exact ultimate stakes were not verified, and a supplier’s corporate identity does not validate its proprietary combination clinically (Indena history; Indena governance model).
Niak’s own contact page identifies a factory near Gorgan, Iran; that is not proof that all headquarters functions are based there. Its history describes an original group of professional investors. Current individual stakes and ultimate control were not established (company factory location; company history).
Documented financial relationships
Linked relationships:
- Lichtwer’s German business sponsored the dyspepsia trial. Lichtwer UK was represented in IBS-report authorship; Walker’s 279-person patient cohort was German (dyspepsia trial; Walker; Bundy).
- 3i documented a 2004 investment; a transaction adviser describes the later brand-rights sale by 3i, Clarat and management to Klosterfrau (3i report; June 2006 transaction).
- Hepar-SL appears in Klosterfrau’s current portfolio. The Doerenkamp Foundation’s historical business link is documented, while exact current ownership stakes remain unverified (brand portfolio; foundation history).
- Indena’s corporate records identify Italy’s IdB Holding as its parent; Indena employees and funded editorial assistance appear in the artichoke-plus-ginger study (corporate history; governance model; combination-study disclosures).
- Niak Pharmaceuticals and Baqiyatallah University supported the Panahi liver study (original funding acknowledgment).
- The SteatoChoke registry names a Saarland institutional budget. The paper declares no specific grant or financial relationships; product procurement terms remain unknown (registry funding; paper declarations).
The core digestive publications discussed here come from German and UK research programs linked to a small number of commercial preparations. Multiple papers or brand names do not automatically provide independent replication. Patient recruitment location, extract manufacture and company headquarters are distinct facts; nationality itself is not a credibility grade.
Regulatory status
European Union and national medicines
EMA recognizes specified artichoke-leaf preparations for traditional relief of digestive complaints, including fullness, bloating and flatulence. Its assessment did not establish a well-established-use indication from adequate clinical evidence. This is a traditional-use framework, with national authorities responsible for individual products. EMA public explanation, assessment conclusion
EMA adopted an addendum in January 2025 reviewing newer information. A periodic review does not constitute authorization for SIBO, liver detoxification or every marketed preparation. 2025 addendum
United States
A dietary supplement's presence on the market is not FDA preapproval of safety and effectiveness. Treatment claims should not be inferred from a supplement label or a study on a differently regulated foreign medicine. FDA supplement guidance
Frequently asked questions
Does artichoke extract help bloating?
The cited dyspepsia trial provides a preliminary symptom signal, rated low certainty by Cochrane, with manufacturer sponsorship. It does not establish a dependable benefit for every person with bloating. Bloating has several possible causes (Cochrane assessment; NIDDK causes).
Does it treat SIBO or improve the migrating motor complex?
The evidence discussed here does not establish either claim for isolated artichoke leaf extract. Lazzini’s small artichoke-plus-ginger study measured post-meal ultrasound gastric area in healthy people, not SIBO eradication or the migrating motor complex (original combination pilot).
Is the 26.4% IBS figure a cure rate?
No. It was a relative before-and-after reduction in reported IBS incidence within a post-hoc subset, without a placebo comparison. It is not the probability that a consumer will be cured (Bundy original abstract).
Is more bile always helpful?
No. Bile-related symptoms need an appropriate diagnosis; the EMA monograph contraindicates the listed medicinal preparations in gallstones, obstruction and other specified liver or biliary disorders (EMA contraindications).
Is “standardized to cynarin” enough to match a study?
No. Plant part, solvent, extract ratio, analytical definition, actual extract dose and other ingredients matter. In SteatoChoke, the specification was total polyphenols expressed as cynarine; it should not be rewritten as a dose of chemically pure cynarin (original formulation description; different product specification).
Why include a positive study but give an insufficient grade?
The result and its financing are separate questions. A manufacturer-sponsored trial can be informative without being an independent replication. Here, Cochrane also rated the single dyspepsia trial low certainty because of unclear selective-reporting risk and imprecision; the IBS reports lack placebo controls (Cochrane; Walker; Bundy).
Sources and funding notes
The tiers describe the financial relationships identified in the records reviewed here: 1, no relevant stake disclosed or identified in those records; 2, indirect ties; 3, an interested party; 4, direct commercial production/support; U, unresolved provenance. They are provisional editorial labels, not a complete funding-chain or ownership certificate. Credibility A–D is assessed separately. Corporate documents and regulated labels can verify their own facts while retaining commercial provenance.
| Source | Funding, ownership and country | Tier / credibility | Accuracy incentive and remaining gap |
|---|---|---|---|
| Holtmann 2003 | Germany; Lichtwer sponsorship and author; contract-research authors also present | 4 / C | Controlled design and accountable report; direct commercial stake |
| Cochrane 2023 | Researcher support from Chilean and German universities; no external support and no known conflicts declared | 1 / B, provisional review-level assessment | Transparent review process; editor-author recused from manuscript editing. Underlying Lichtwer-sponsored trial remains separate. |
| Marakis 2002 | UK university program; full budget/procurement unresolved; related reports have Lichtwer ties | U / B provisional | Published methods; no placebo and missing funding detail |
| Bundy 2004 | UK; Lichtwer-affiliated coauthor; full financing not established from primary accessible record | 4 / C | Research reputation; post-hoc uncontrolled subgroup |
| Walker 2001 | German patient cohort; UK/German authors, including Lichtwer UK coauthor; trial cash and supply terms unreported | 4 / C | Surveillance subgroup lacks complete IBS diagnostic criteria and a placebo control. |
| Kirchhoff 1994 | Germany; branded Hepar-SL study; sponsor and procurement terms unresolved | U / B provisional | Objective acute measurement; route and outcome do not establish oral symptom benefit |
| Lazzini 2016 | Italy; Indena employee authors and company-funded editorial assistance, alongside a no-conflicts declaration | 4 / C | Eleven healthy participants, artichoke plus ginger, one-hour ultrasound outcome; separate trial cash/procurement terms unclear. |
| Panahi 2018 | Niak Pharmaceuticals and Baqiyatallah University supported the study; no competing interests declared | 4 / C | Alternating assignment, baseline imbalances, per-protocol analysis and conflicting participant totals weaken the short surrogate findings. |
| Holländer 2026 original paper; primary abstract | German academic investigators; no specific grant or commercial/financial relationships declared. Registry institutional budget; procurement terms unknown | U / B, provisional procurement assessment | Small single-blind pilot, retrospective registration, diet cointervention and surrogate outcomes. Indexed pertinent original sections read; full PDF/supplements unavailable. |
| SteatoChoke registry | Investigator-entered university record, Germany; institutional budget/no external funds stated | U / B provisional for sponsor declaration | Time-stamped public record; host does not independently audit every entry |
| Jerusalem-artichoke inulin registry | Japan; Melodian listed as funder and investigator organization, IMEQRD as sponsor; sponsor-entered UMIN record | 4 / C for provenance, used for identity only | Defines a different intervention; not used as benefit evidence |
| Caco-2 laboratory study | Spanish national/regional, European and research-network support; no competing interests declared | 1 / B, provisional disclosed-funding assessment | Waste-derived extracts and cell oxidative-stress responses; not clinical gut-barrier efficacy. Ultimate funding/procurement not fully traced. |
| EMA overview | EU medicines agency; official regulatory source | 2 / A for regulatory scope | Traditional-use and preparation-specific assessment, not independent replication or a trial-finance audit. |
| EMA public summary | Same EU institution | 2 / A | Public explanation; preparation-specific and traditional-use limits |
| EMA monograph | Same EU institution | 2 / A | Adopted regulatory text; missing interaction reports do not prove compatibility |
| EMA assessment | Same EU institution | 2 / A for assessment scope | Literature review; some underlying studies are commercially linked |
| EMA 2025 addendum | Same EU institution | 2 / A | Dated update; preclinical findings remain preclinical |
| Hepar-SL professional information | Cassella-med, Germany; manufacturer-origin regulated medicine document | 4 / C | Label accountability; used for formulation, warnings and regulatory identity |
| Hepar-SL marketing | Commercial German brand website | 4 / D | Sales incentive; claims described, not accepted as independent evidence |
| NIDDK indigestion guidance | US federal NIH institute | 1 / A for health guidance | Public accountability; no artichoke efficacy estimate |
| NHS gallstones | UK publicly funded health service | 1 / A | Clinical safety guidance; individual diagnosis still needed |
| NHS anaphylaxis | UK public health service | 1 / A | Emergency guidance; not an ingredient-specific incidence estimate |
| FDA supplement guidance | US federal regulator; official dietary-supplement guidance | 2 / A for legal scope | Statutory responsibilities and premarket-approval limits; not a clinical benefit endorsement or agency-finance audit. |
| 3i 2004 report | UK investment company, interested primary financial record | 4 / C | Filing accountability; historical holding does not establish current ownership |
| Ferber transaction record | German transaction adviser; fee-based advisory business | 3 / C | Public deal attribution; exact stakes/brand transfer chronology incomplete |
| Klosterfrau brand page | Commercial group, Germany | 4 / C for portfolio, D for promotion | Brand identity; its 2005 date differs from the wider 2006 transaction record |
| Klosterfrau structure | Group self-disclosure; central headquarters Cologne, Germany | 4 / C | Corporate accountability; ultimate ownership not fully traced |
| Doerenkamp Foundation account | Swiss foundation/grant program with historical business link | 3 / C | Public mission statement; not a current cap table or trial-funding record |
| Indena history | Italian supplier; IdB parent and family history self-disclosed | 4 / C | Corporate identity; ultimate percentages not verified |
| Niak factory location | Iranian medicine company; own contact disclosure identifies a factory near Gorgan | 4 / C | Factory address does not establish the complete headquarters location or clinical efficacy. |
| Niak history | Iranian company; historical investor-group self-description | 4 / C | Corporate accountability; current stakes unknown |
| Indena governance model | Italian commercial group; company model describes IdB parent control | 4 / C | Relevant original indexed corporate passage only; full current beneficial stakes and clinical funding remain unverified. |
Scope: digestive claims and relevant liver/biliary safety context. This is not a complete cardiovascular, liver-treatment or product-market review. Some original papers, procurement terms and ultimate ownership records remain unavailable or unreported; those limits are retained rather than treated as proof of independence.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
